Competition watchdog fines big pharma duo £70m

22-07-2022

Staff writer

Competition watchdog fines big pharma duo £70m

marbury / Shutterstock.com

The pair are rapped for overcharging the NHS | Unfair prices for an epilepsy drug lasted four years | Costs leapt from £2m to £50m in one year after the companies' “illegal exploitation” of market position.


Competition and Markets Authority, Pfizer, Flynn Pharma, competition, epilepsy, NHS pharmaceuticals

LSIPR